Get the Stockscreener App
1.71
2.00%
-0.04
Inhibikase Therapeutics Inc stock is traded at $1.71, with a volume of 75,309.
It is down -2.00% in the last 24 hours and down -7.30% over the past month.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
See More
Previous Close:
$1.75
Open:
$1.77
24h Volume:
75,309
Relative Volume:
0.31
Market Cap:
$127.50M
Revenue:
-
Net Income/Loss:
$-19.57M
P/E Ratio:
-0.5463
EPS:
-3.13
Net Cash Flow:
$-17.24M
1W Performance:
-0.87%
1M Performance:
-7.30%
6M Performance:
-23.09%
1Y Performance:
+24.28%
1-Day Range:
$1.70
$1.88
1-Week Range:
$1.415
$1.88
52-Week Range:
$1.12
$4.20
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
678-392-3419
Address
3350 RIVERWOOD PARKWAY SE, SUITE 1900, ATLANTA
Compare IKT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.715 | 112.26M | 0 | -19.57M | -17.24M | -3.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
393.61 | 96.01B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.28 | 57.86B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.56 | 57.02B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
644.68 | 39.10B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
304.30 | 34.45B | 3.81B | -644.79M | -669.77M | -6.24 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Stock (IKT) Latest News
Using fundamentals and technicals on Inhibikase Therapeutics Inc.Weekly Stock Summary & Risk Adjusted Buy and Sell Alerts - Newser
How institutional ownership impacts Inhibikase Therapeutics Inc. stockJuly 2025 Market Mood & Weekly Setup with High ROI Potential - Newser
Automated trading signals detected on Inhibikase Therapeutics Inc.Portfolio Return Report & Accurate Buy Signal Notifications - Newser
Real time pattern detection on Inhibikase Therapeutics Inc. stockBollinger Band Squeeze and Expansion Analysis - Newser
Chart based analysis of Inhibikase Therapeutics Inc. trendsHigh Accuracy Trade Setup Identification - Newser
Visual analytics tools that track Inhibikase Therapeutics Inc. performanceEarnings Impact and Stock Reaction Analysis - Newser
Visual trend scoring systems applied to Inhibikase Therapeutics Inc.Short-Term Support and Resistance Forecast - Newser
New Product Launches: Will They Boost Inhibikase Therapeutics Inc. Stock in 2025Free Watchlist for Smart Swing Trading - Newser
Key metrics from Inhibikase Therapeutics Inc.’s quarterly dataSwing Watchlist With Tight Stop Placement - Newser
What indicators show strength in Inhibikase Therapeutics Inc.Free Real Market Momentum Signal Generator - Newser
How high can Inhibikase Therapeutics Inc. stock goMonthly Long-Term Market Recap and Summary - Newser
Risk vs reward if holding onto Inhibikase Therapeutics Inc.Tactical Trade Setup With Entry Optimizer - Newser
What risks could impact Inhibikase Therapeutics Inc. stock performanceFree Weekly Potential Breakout Stock List - Newser
Inhibikase Therapeutics Inc. recovery potential after sell offSmart Risk Strategy with Entry Optimization - Newser
How Inhibikase Therapeutics Inc. stock performs during market volatilitySafe Entry Screening with Data Backed Analysis - Newser
Published on: 2025-08-06 00:58:01 - Newser
Published on: 2025-08-04 16:30:58 - metal.it
What institutional investors are buying Inhibikase Therapeutics Inc. stockMarket-leading capital gains - Jammu Links News
How does Inhibikase Therapeutics Inc. compare to its industry peersOutstanding capital growth - Jammu Links News
Is Inhibikase Therapeutics Inc. stock overvalued or undervaluedFastest return on investment - Jammu Links News
What is the risk reward ratio of investing in Inhibikase Therapeutics Inc. stockConsistent high-performance stocks - Jammu Links News
When is Inhibikase Therapeutics Inc. stock expected to show significant growthBuild a portfolio that outperforms the market - Jammu Links News
What are the latest earnings results for Inhibikase Therapeutics Inc.Unlock powerful investment tools for free - Jammu Links News
Is it the right time to buy Inhibikase Therapeutics Inc. stockDiscover market opportunities with expert help - Jammu Links News
Candlestick signals on Inhibikase Therapeutics Inc. stock todayFree Early Breakout Entry Point Notifications - newser.com
What makes Inhibikase Therapeutics Inc. stock price move sharplyIdentify winners with top-tier analysis - Jammu Links News
What drives Inhibikase Therapeutics Inc. stock priceMaximize gains with data-driven trading alerts - Jammu Links News
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Inhibikase Therapeutics Inc Stock (IKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kush Arvind | Director |
Oct 21 '24 |
Buy |
1.37 |
145,000 |
198,650 |
145,000 |
| Munshi Amit | Director |
Oct 21 '24 |
Buy |
1.37 |
365,000 |
500,050 |
365,000 |
0.71%
0.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):